This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Gilead Starts Testing Remdesivir Inhaled Version for Coronavirus
by Zacks Equity Research
Gilead (GILD) begins a phase I study to evaluate the safety, tolerability and pharmacokinetics of an investigational, inhaled solution of remdesivir for coronavirus.
Biotech Stock Roundup: REGN Initiates Coronavirus Study, NVAX Surges & More
by Zacks Equity Research
The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.
Company News for Jul 8, 2020
by Zacks Equity Research
Companies In The News Are: WMT, NVAX, DOCU, REGN.
Regeneron Initiates Studies on Experimental Coronavirus Drug
by Zacks Equity Research
Regeneron (REGN) announces initiation of late-stage studies evaluating REGN-COV2 for the treatment and prevention of COVID-19.
Novartis Gets EC Approval for Enerzair Breezhaler for Asthma
by Zacks Equity Research
Novartis (NVS) gets EC approval for Enerzair Breezhaler as a maintenance treatment for asthma.
Company News for Jul 7, 2020
by Zacks Equity Research
Companies in The News Are: BRK.B, D, UBER, REGN, SINA.
Gilead's Coronavirus Drug Gets Conditional Approval in Europe
by Zacks Equity Research
Gilead (GILD) gets conditional marketing authorization for Veklury (remdesivir) as a treatment for SARS-CoV-2 infection by the European Commission.
Sanofi/Regeneron's Kevzara Fails in Phase III Coronavirus Study
by Zacks Equity Research
Sanofi (SNY) and Regeneron discontinue U.S.-based phase III coronavirus study on Kevzara following failure to achieve improvement in hospitalized patients with severe COVID-19 patients of statistical significance.
Amgen Gets Favorable Appeals Court Ruling for Enbrel Patent
by Zacks Equity Research
An appeals court ruled in Amgen's (AMGN) favor in a case challenging the validity of two patents on its top-selling medicine, Enbrel.
REGN vs. TECH: Which Stock Is the Better Value Option?
by Zacks Equity Research
REGN vs. TECH: Which Stock Is the Better Value Option?
Vertex's Triple Combo Cystic Fibrosis Pill Gets CHMP Backing
by Zacks Equity Research
Vertex (VRTX) is seeking approval in Europe for its triple combo pill, Kaftrio in combination with Kalydeco to treat cystic fibrosis in patients aged 12 and older with most common genotypes.
AbbVie's Eye Disorder Candidate Gets Complete Response Letter
by Zacks Equity Research
AbbVie (ABBV) unit Allergan's abicipar pegol demonstrates unfavorable benefit-risk ratio in patients with nAMD, an eye disorder. The FDA issues a complete response letter.
Invest in the Future With Megatrend ETFs
by Neena Mishra
These ETFs invest in fast growing areas like robotics and AI, genomics and cybersecurity.
Regeneron (REGN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Regeneron (REGN) closed at $628.76 in the latest trading session, marking a +0.04% move from the prior day.
Sanofi Expands Agreement With Translate Bio for mRNA Vaccines
by Zacks Equity Research
Sanofi (SNY) and Translate Bio expand their tie-up to develop mRNA vaccines for infectious diseases. The companies are already developing a mRNA vaccine candidate to combat COVID-19.
Regeneron Gets FDA Nod for Dupixent 300 Mg Pre-Filled Pen
by Zacks Equity Research
Regeneron (REGN) wins FDA approval for a 300-mg, single-dose, pre-filled pen for asthma drug, Dupixent.
Company News for Jun 22, 2020
by Zacks Equity Research
Companies In The News Are: PENN, KMX, REGN, AAPL.
Top Stock Reports for Facebook, Adobe & Amgen
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), Adobe Systems (ADBE) and Amgen (AMGN).
Should You Invest in the Invesco Dynamic Biotechnology Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
PTC Therapeutics to Commence Phase II/III Coronavirus Study in US
by Zacks Equity Research
PTC Therapeutics (PTCT) gets an FDA sanction to begin a phase II/III study on its DHODH inhibitor PTC299 as a potential treatment of COVID-19. The study will start in the United States shortly.
Sanofi (SNY) to Create Dedicated Vaccine Center in France
by Zacks Equity Research
Sanofi (SNY) plans to invest almost $690 billion to develop a new production site and research center in France with both dedicated to vaccines.
Biotech Stock Roundup: REGN Begins Coronavirus Study, VRTX, BIIB Give Updates
by Zacks Equity Research
The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.
Regeneron (REGN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Regeneron (REGN) closed at $592.90 in the latest trading session, marking a +0.39% move from the prior day.
Momenta (MNTA) Up on Positive Data From Generalized MG Drug
by Zacks Equity Research
Momenta (MNTA) stock up on the announcement of positive data from a mid-stage study on nipocalimab for the indication of gMG.
3 Big Biotechs Poised for Growth Amid Coronavirus Pandemic
by Ekta Bagri
We highlight a few leading players from the biotech sector, who are likely to see a good run as the year progresses.